BRPI0914916A2 - anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos - Google Patents
anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmosInfo
- Publication number
- BRPI0914916A2 BRPI0914916A2 BRPI0914916A BRPI0914916A BRPI0914916A2 BR PI0914916 A2 BRPI0914916 A2 BR PI0914916A2 BR PI0914916 A BRPI0914916 A BR PI0914916A BR PI0914916 A BRPI0914916 A BR PI0914916A BR PI0914916 A2 BRPI0914916 A2 BR PI0914916A2
- Authority
- BR
- Brazil
- Prior art keywords
- interleukin
- antibodies
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08159344 | 2008-06-30 | ||
PCT/EP2009/058155 WO2010000721A1 (en) | 2008-06-30 | 2009-06-30 | Anti-human interleukin-20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0914916A2 true BRPI0914916A2 (pt) | 2015-10-20 |
Family
ID=40947599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0914916A BRPI0914916A2 (pt) | 2008-06-30 | 2009-06-30 | anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (4) | US8287861B2 (pt) |
EP (1) | EP2297203A1 (pt) |
JP (1) | JP2011526591A (pt) |
KR (1) | KR20110039218A (pt) |
CN (1) | CN102137871A (pt) |
AU (1) | AU2009265808B2 (pt) |
BR (1) | BRPI0914916A2 (pt) |
CA (1) | CA2728685A1 (pt) |
IL (1) | IL209717A0 (pt) |
MX (1) | MX2010013565A (pt) |
RU (1) | RU2011101969A (pt) |
TW (1) | TW201022288A (pt) |
WO (1) | WO2010000721A1 (pt) |
ZA (1) | ZA201008993B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2143733A1 (en) * | 2003-11-21 | 2010-01-13 | ZymoGenetics, Inc. | ANTI-IL-20 antibodies and binding partners and methods of using in inflammation |
RU2011101969A (ru) | 2008-06-30 | 2012-08-10 | Ново Нордиск А/С (DK) | Антитела к человеческому интерлейкину-20 |
US8454956B2 (en) * | 2009-08-31 | 2013-06-04 | National Cheng Kung University | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
WO2011109452A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
CN103797029B (zh) | 2011-05-17 | 2016-08-17 | 洛克菲勒大学 | 人类免疫缺陷病毒中和抗体及其使用方法 |
MX2014009490A (es) | 2012-02-10 | 2014-08-29 | Novo Nordisk As | Metodos relacionados con el tratamiento de enfermedades y trastornos inflamatorios. |
WO2013164440A1 (en) | 2012-05-03 | 2013-11-07 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
EP2850099B1 (en) | 2012-05-14 | 2017-01-18 | Novo Nordisk A/S | Stabilised protein solutions |
WO2014006230A1 (en) | 2012-07-06 | 2014-01-09 | Novo Nordisk A/S | Il-20 epitopes and il-20 ligands |
WO2014015133A1 (en) * | 2012-07-19 | 2014-01-23 | National Cheng Kung University | Treatment of osteoarthritis using il-20 antagonists |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US8852588B2 (en) * | 2012-08-07 | 2014-10-07 | National Cheng Kung University | Treating allergic airway disorders using anti-IL-20 receptor antibodies |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US20150361131A1 (en) * | 2012-12-28 | 2015-12-17 | Novo Nordisk A/S | High temperature dead end antibody filtration |
US20140314741A1 (en) * | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
MX2016008472A (es) * | 2013-12-26 | 2016-10-28 | Mitsubishi Tanabe Pharma Corp | Anticuero monoclonal neutralizador de anti-il-33-humana. |
CN106459182B (zh) | 2013-12-30 | 2021-09-03 | 岸迈生物科技有限公司 | 串联fab免疫球蛋白及其用途 |
US9376490B2 (en) * | 2014-04-01 | 2016-06-28 | National Cheng Kung University | Treatment of inflammatory pain using IL-20 antagonists |
EP3224279B1 (en) * | 2014-11-24 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r. |
JP6501650B2 (ja) * | 2015-06-25 | 2019-04-17 | 田辺三菱製薬株式会社 | ヒト抗il−33中和モノクローナル抗体 |
CA3011746A1 (en) | 2016-02-06 | 2017-08-10 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
JP7177446B2 (ja) | 2017-08-31 | 2022-11-24 | 田辺三菱製薬株式会社 | Il-33アンタゴニストを含む子宮内膜症治療剤 |
CA3087276A1 (en) * | 2018-01-17 | 2019-07-25 | Eli Lilly And Company | Compounds and methods targeting interleukin-19 |
TWI691930B (zh) | 2018-09-19 | 2020-04-21 | 財團法人工業技術研究院 | 基於神經網路的分類方法及其分類裝置 |
WO2021086997A1 (en) * | 2019-10-28 | 2021-05-06 | LBL Biotechnology Inc. | Treating tissue fibrosis and/or injury and-or organ failure with interleukin 24 or interleukin 20 antagonist |
US11661450B2 (en) * | 2020-04-22 | 2023-05-30 | LBL Biotechnology Inc. | Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor |
CN111647081B (zh) * | 2020-04-28 | 2022-06-03 | 武汉百杰康生物科技有限公司 | 一种重组小鼠抗人白介素19单克隆抗体、制备方法和应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK261490D0 (da) | 1990-10-31 | 1990-10-31 | Novo Nordisk As | New pharmaceutical compound |
JP5191619B2 (ja) | 1997-11-26 | 2013-05-08 | ザイモジェネティクス, インコーポレイテッド | 哺乳類のサイトカイン様ポリペプチド−10 |
US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
EP1616575B1 (en) | 1999-12-23 | 2012-06-06 | ZymoGenetics, Inc. | Method for treating inflammation |
WO2002030463A2 (en) | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7022289B1 (en) * | 2001-10-10 | 2006-04-04 | The United States Of America As Represented By The Secretary Of The Army | Chemical and biological sampling device and kit and method of use thereof |
IL161978A0 (en) | 2001-12-17 | 2005-11-20 | Zymogenetics Inc | Method for treating cervical cancer |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
KR20110091598A (ko) | 2003-03-24 | 2011-08-11 | 지모제넥틱스, 인코포레이티드 | 항-il-22ra 항체 및 결합 파트너 및 염증에 있어서의 사용 방법 |
US7435800B2 (en) * | 2003-05-23 | 2008-10-14 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
MEP31508A (en) * | 2003-07-15 | 2010-10-10 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
EP2087905A2 (en) * | 2003-08-08 | 2009-08-12 | Novo Nordisk A/S | Interleukin-20 for treating and diagnosing conditions associated with neovascularisation |
EP2143733A1 (en) * | 2003-11-21 | 2010-01-13 | ZymoGenetics, Inc. | ANTI-IL-20 antibodies and binding partners and methods of using in inflammation |
AU2006212807A1 (en) * | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
US7525604B2 (en) * | 2005-03-15 | 2009-04-28 | Naxellent, Llc | Windows with electrically controllable transmission and reflection |
WO2007081465A2 (en) | 2005-12-09 | 2007-07-19 | Chi-Mei Medical Center | Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation |
KR20090013763A (ko) * | 2006-03-23 | 2009-02-05 | 기린 파마 가부시끼가이샤 | 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체 |
EP2043708B1 (en) | 2006-07-15 | 2010-12-29 | Novo Nordisk A/S | Medical delivery system with asymmetrical coding means |
RU2009111138A (ru) | 2006-10-12 | 2010-11-20 | Вайет (Us) | Способы и композиции с уменьшенной опалесценцией |
CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
US7611705B2 (en) * | 2007-06-15 | 2009-11-03 | National Cheng Kung University | Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases |
BRPI0821658B8 (pt) | 2007-12-14 | 2021-05-25 | Novo Nordisk As | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos |
CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
RU2011101969A (ru) | 2008-06-30 | 2012-08-10 | Ново Нордиск А/С (DK) | Антитела к человеческому интерлейкину-20 |
RU2562114C2 (ru) | 2008-12-22 | 2015-09-10 | Ново Нордиск А/С | Антитела против ингибитора метаболического пути тканевого фактора |
CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
US8603470B1 (en) * | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
-
2009
- 2009-06-30 RU RU2011101969/10A patent/RU2011101969A/ru unknown
- 2009-06-30 CA CA2728685A patent/CA2728685A1/en not_active Withdrawn
- 2009-06-30 US US12/601,164 patent/US8287861B2/en not_active Expired - Fee Related
- 2009-06-30 BR BRPI0914916A patent/BRPI0914916A2/pt not_active IP Right Cessation
- 2009-06-30 CN CN2009801333945A patent/CN102137871A/zh active Pending
- 2009-06-30 AU AU2009265808A patent/AU2009265808B2/en not_active Expired - Fee Related
- 2009-06-30 JP JP2011515424A patent/JP2011526591A/ja not_active Withdrawn
- 2009-06-30 WO PCT/EP2009/058155 patent/WO2010000721A1/en active Application Filing
- 2009-06-30 MX MX2010013565A patent/MX2010013565A/es active IP Right Grant
- 2009-06-30 KR KR1020107029244A patent/KR20110039218A/ko not_active Application Discontinuation
- 2009-06-30 TW TW098121982A patent/TW201022288A/zh unknown
- 2009-06-30 EP EP09772421A patent/EP2297203A1/en not_active Withdrawn
-
2010
- 2010-12-02 IL IL209717A patent/IL209717A0/en unknown
- 2010-12-14 ZA ZA2010/08993A patent/ZA201008993B/en unknown
-
2012
- 2012-09-07 US US13/606,642 patent/US20130039923A1/en not_active Abandoned
-
2013
- 2013-08-21 US US13/972,549 patent/US20140194599A1/en not_active Abandoned
- 2013-08-21 US US13/972,525 patent/US20140141001A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2010013565A (es) | 2011-01-14 |
AU2009265808A1 (en) | 2010-01-07 |
IL209717A0 (en) | 2011-02-28 |
JP2011526591A (ja) | 2011-10-13 |
CN102137871A (zh) | 2011-07-27 |
EP2297203A1 (en) | 2011-03-23 |
WO2010000721A1 (en) | 2010-01-07 |
US20110091475A1 (en) | 2011-04-21 |
AU2009265808B2 (en) | 2014-10-23 |
KR20110039218A (ko) | 2011-04-15 |
US20140141001A1 (en) | 2014-05-22 |
US8287861B2 (en) | 2012-10-16 |
CA2728685A1 (en) | 2010-01-07 |
ZA201008993B (en) | 2012-01-25 |
RU2011101969A (ru) | 2012-08-10 |
TW201022288A (en) | 2010-06-16 |
US20130039923A1 (en) | 2013-02-14 |
US20140194599A1 (en) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0914916A2 (pt) | anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos | |
BRPI0922248A2 (pt) | eletrodo e método de produção do mesmo | |
BRPI0922440A2 (pt) | dispositivo protético e método de fabricação do mesmo . | |
BRPI0916243A2 (pt) | suportes ortodônticos e respectivo método de produção | |
BRPI1007477A2 (pt) | método, e, composição de tratamento de poço | |
BRPI0906305A2 (pt) | artigo absorvente e método de produção do mesmo | |
BR112013010725A2 (pt) | método, e, composição | |
BRPI0906668A2 (pt) | bocal e inalador e método de produção de bocal | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
BR112012001172A2 (pt) | artigo, e, método | |
BRPI0917129A2 (pt) | método de fabricação de fralda | |
BRPI0923011A2 (pt) | método, e, produto de programa de computador | |
BRPI0909367A2 (pt) | calçado e método de fabricação do mesmo | |
BRPI0912317A2 (pt) | método de autenticação | |
BR112012003863A2 (pt) | aparelho e método de processamento de informação, e, programa | |
DK2287230T3 (da) | Docetaxel polymer derivative, method for producing same and use of same | |
BR112013013584A2 (pt) | endoscópio, e, método | |
BR112012013954A2 (pt) | derivado de ácido hialurônico, método de preparação do derivado de ácido hialurônico e método de modificação do derivado de ácido hialurônico | |
BRPI1015167A2 (pt) | aparelho e método de processamento de informação, e, programa | |
BRPI1009418A2 (pt) | nanocapsula de proteina, metodo de pdroduzir uma nanocapsula, e metodo de distribuir uma proteina | |
BRPI1012863A2 (pt) | aparelho e método de processamento de informação, e, programa | |
BR112013012563A2 (pt) | bactéria recombinante e processo de elaboração de glicerol | |
BR112013015977A2 (pt) | transformador não linear e método de produção do mesmo. | |
BRPI0908183A2 (pt) | membro embalado e método de produção do mesmo | |
BR112012008229A2 (pt) | método, e aparelho |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |